James Niedel
Director/Board Member at Tioga Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stuart J. M. Collinson | M | 64 |
Tioga Pharmaceuticals, Inc.
 Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA.
Glaxo Wellcome Plc
| 24 years |
| Clarence Machado | M | 60 | 10 years | |
| Fred Middleton | M | 74 | 6 years | |
| Michael Alrutz | M | 54 | 12 years | |
| Robert Meyer | M | 65 | 6 years | |
| Robert Lefkowitz | M | 80 |
Duke University Medical Center
| 51 years |
| Joann L. Data | M | 79 |
Duke University Medical Center
| 42 years |
| Arno Hartmann | M | - |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | - |
| Martin C. Münchbach | M | 54 |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | 19 years |
| Odin Naderer | M | - | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| George R. Painter | M | - | 12 years | |
| Kenneth Moch | M | 69 | 5 years | |
| Howard Robin | M | 71 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 5 years |
| Timothy J. Wollaeger | M | 80 | 16 years | |
| Chris Christoffersen | M | 86 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 10 years |
| M. Berrey | M | 57 | 7 years | |
| Joseph T. Schepers | M | 65 | 3 years | |
| Nassim Usman | M | 64 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 years |
| Richard Sykes | M | 79 |
Glaxo Wellcome Plc
| 5 years |
| Ronald Renaud | M | 55 | 6 years | |
| Douglas J. Ringler | M | - |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 years |
| Patti Ketchner | F | - |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 years |
| Wende Hutton | F | 63 | - | |
| Herman Waldmann | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 years |
| Christopher Viehbacher | M | 64 |
Glaxo Wellcome Plc
| 13 years |
| Timothy Trost | M | 66 | 7 years | |
| Art Pappas | M | 76 | 3 years | |
| James Daly | M | 62 | 6 years | |
| Ernest Mario | M | 85 | - | |
| Edward F. Greissing | M | 73 | 3 years | |
| Andrea Corcoran | F | 61 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 years |
| Patricia P. Ketchner | F | - |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 years |
| Catherine Lynch Gilliss | M | 75 | 9 years | |
| Lisa Ricciardi | F | 64 | - | |
| Robert Alexander Ingram | M | 81 |
Glaxo Wellcome Plc
| 14 years |
| John Leonard | M | 66 | 4 years | |
| R. Greer | M | 65 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 6 years |
| Moise Khayrallah | M | - |
Glaxo Wellcome Plc
| 9 years |
| Joseph F. Rutledge | M | - | - | |
| Kevin Reeves | M | - | - | |
| Michelle L. Rose | M | - | 8 years | |
| David Lawrence | M | 61 |
Glaxo Wellcome Plc
| 13 years |
| Philip Bedford | M | - |
Glaxo Wellcome Plc
| - |
| Roberto Guzman | M | - | - | |
| Thomas A. Pitler | M | 65 | - | |
| Michael R. Starkenburg | M | 52 |
Sprout Group
 Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 3 years |
| Essy Mozaffari | M | - | - | |
| Harren Jhoti | M | 61 |
Glaxo Wellcome Plc
| 8 years |
| Lutz Lingnau | M | 81 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | - |
| Robert M. Kirsch | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Mark O’Mahony | M | 53 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 11 years |
| J. Kenneth Charles Knowles | M | 77 |
Glaxo Wellcome Plc
| 2 years |
| Kwok Cheung Li | M | 79 |
Glaxo Wellcome Plc
| 3 years |
| William Rapeport | M | - |
Glaxo Wellcome Plc
| - |
| Linda M. Richardson | F | 60 | 5 years | |
| Mary E. Taylor | F | 65 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Donna M. Jarlenski | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 2 years |
| Titus M. F. M. Plattel | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Robert J. DiVasto | M | 68 |
Glaxo Wellcome Plc
| 10 years |
| David Eckland | M | - |
Glaxo Wellcome Plc
| 7 years |
| Teresa Regan | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Phil Thomson | M | - |
Glaxo Wellcome Plc
| 5 years |
| Jung Choi | F | 54 | 2 years | |
| Charlotte McKee | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Antonin Rollet de Fougerolles | M | 59 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 1 years |
| Vijay K. Lathi | M | 49 |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 6 years |
| Beth Hoffman | F | - |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 3 years |
| Gregory Weaver | M | 68 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | - |
| Tim Tyson | M | 71 |
Glaxo Wellcome Plc
| 4 years |
| Barry A. Polisky | M | 78 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 5 years |
| Dennis Langer | M | 73 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 1 years |
| Roberto Guerciolini | M | 69 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 2 years |
| Rodman L. Drake | M | 80 | 1 years | |
| Martin Schmieg | M | 62 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 1 years |
| John Freund | M | 70 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| William Nichols | M | 55 | 6 years | |
| Keith Geeslin | M | 71 |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 19 years |
| Wayne T. Hockmeyer | M | 79 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Dan Kisner | M | 77 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 10 years |
| Thomas A. Shea | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Kathy LaPorte | F | 62 |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 11 years |
| Stefan Ryser | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| John W. Littlechild | M | 72 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 7 years |
| J. Michael French | M | 63 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 2 years |
| Elizabeth Czerepak | F | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 years |
| Patrick J. Boroian | M | - |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 10 years |
| Christopher Scoggins | M | - |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 1 years |
| Trevor Phillips | M | 63 |
Glaxo Wellcome Plc
| 7 years |
| Craig Slutzkin | M | - |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 3 years |
| Paul Sekhri | M | 66 |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 1 years |
| Ron Hunt | M | 59 |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | 6 years |
| Louis Vaickus | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 9 years |
| Farah Champsi | F | 62 | 4 years | |
| Doug Onsi | M | 55 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Douglas Fambrough | M | 55 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 3 years |
| Andrew Firlik | M | - |
Sprout Group
Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | - |
| Ian Smith | M | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 7 years |
| Clive Dix | M | 70 |
Glaxo Wellcome Plc
| - |
| Stephen Hoffman | M | 70 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Heather Knight | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 84 | 84.00% |
| United Kingdom | 17 | 17.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Niedel
- Personal Network
